The PanAMP multicenter study evaluates how PanCystPro results influence clinician management decisions for patients with pancreatic cystic lesions.
Amplified Sciences has launched PanAMP, a multicenter clinical utility study for its PanCystPro assay, according to the company.
The real-world study involves patients with radiographically confirmed pancreatic cysts. It aims to evaluate the impact of the assay on patient management decisions made by healthcare providers.
PanCystPro helps risk-stratify patients with pancreatic cystic lesions, which are known precursors for pancreatic cancer,, says Diana Caldwell, CEO of Amplified Sciences, in a release.
“These cystic lesions are a challenge for many clinicians, and the use of innovative tests like PanCystPro alongside imaging can provide insights on surveillance and treatment strategies for those patients at higher risk for pancreatic cancer,” says Caldwell, CEO of Amplified Sciences, in a release.
Managing these lesions is difficult for clinicians due to persistent diagnostic uncertainty, says Mohammad Al-Haddad, MD, a principal investigator from Indiana University School of Medicine, in a release.
“Incorporating an accurate low-volume test like PanCystPro into the diagnostics workflow has the potential to provide clinicians with more actionable information to determine surveillance frequency and treatment strategies,” says Al-Haddad, MD, a principal investigator from Indiana University School of Medicine, in a release.
Other principal investigators for the PanAMP study include Srinivas Gaddam, MD, of Cedars-Sinai Medical Center; Mandeep Sawhney, MD, of Harvard Medical School and Beth Israel Deaconess Medical Center; and Arvind Trindade, MD, of Rutgers Health and RWJBarnabas Health.
The diagnostic tests from Amplified Sciences are based on the BioMatra optical reporter system. This technology was invented by V Jo Davisson, chief scientific officer of Amplified Sciences and professor of medicinal chemistry and molecular pharmacology at Purdue University.
The company is part of the Purdue Innovates Ventures portfolio and previously completed a $2.6 million Series Seed Preferred capital raise in 2023, according to the company.
Photo caption: Diagnostics life sciences company Amplified Sciences has announced the launch of PanAMP, a real-world, multicenter study to assess the impact of its PanCystPro assay on healthcare providers’ patient management decisions.
Photo credit: Purdue Research Foundation photo/Jennifer Mayberry
